Updated on 17 September 2013
Tiatros' strategy has been to work closely with thought leaders in academia and the healthcare industry in order to create something that makes medical devices smarter and more useful by allowing doctors to ‘pull' useful health data sets from mobile medical devices and biosensors. It is clear that hospital CMIOs do not want to buy more medical devices - they want to be able to obtain better, more relevant data from new mobile medical devices. Furthermore, doctors want the ability to better organize and understand data that they have ‘pulled' from devices - they don't want huge amounts of data just ‘pushed' at them.
These are just a few examples of the CEO's plan to ensure her company is known worldwide for its innovation in medical research, public service and patient care. By joining forces with experts at UCSF Medical Center, she has been able to integrate hundreds of solutions within Tiatros that streamline clinic-to-clinic workflow processes, drive operational efficiencies, and lower the cost of providing health and wellness services. UCSF experts have helped the company understand where communications break down and data gets stuck across healthcare. They have also joined forces with the top clinical research groups to work on gathering research data from the world's newest, and most exciting mobile medical devices. For example, premiere clinical research groups that are leveraging Tiatros to define better ways to handle genomic sequencing data panels so that the information is more useful to doctors.
Throughout this process, the privacy and security of patient records and sensitive communications remains paramount. The University of California Information Security experts independently verified that the Tiatros solution complies with all US privacy and security laws (known as HIPAA regulations), as well as the separate, stringent University of California requirements for healthcare privacy and security. This required a year-long effort that very few digital health companies have even attempted, but is paying big dividends now that Tiatros is in discussions with other top medical centers and several Fortune 500 companies.
Tiatros has also prepared itself to quickly enter the digital health market and align with the thought leaders who are mapping out the future of mobile healthcare. To do this, the company targeted its first commercial product to be sold to premiere clinical research programs that are studying the most innovative products and services for telemedicine, wireless medical devices and biosensors, and genomic health data. This product, called Tiatros Research, is specifically designed to meet the needs of these studies. It is easy to buy, fast to set up, and makes managing a research study intuitive and efficient.
By aligning with the foremost providers of medical research, Tiatros has an extraordinary chance to align itself with the cutting edge of digital health. Doing so allows the company to optimize its solution to support the wave of telemedicine and mobile health and wellness products and services that are changing healthcare for the better worldwide. Tiatros' early growth in this space has been viral-its customers have been introducing the product to their colleagues at different campuses, and selling the product while using it. Tiatros now claims over 20 top US medical institutions in its sales pipeline thanks entirely to its customers and advisors.